Is China facing outbreak of chikungunya virus? What is it? Know the symptoms
According to a report by the South China Morning Post, people who have travelled from chikungunya-affected areas have been advised to self-monitor for symptoms.
Restaurants and hotels have been directed to maintain hygiene and prevent mosquito breeding. Failure to do so may result in heavy fines.
In Foshan city, the worst-affected area, chikungunya patients are required to remain in hospital, where their beds are covered with mosquito nets for protection. They can only be discharged either after testing negative or completing a one-week stay.
Americans planning to travel to China have been urged to exercise increased caution following the outbreak of the chikungunya virus. The US Centers for Disease Control and Prevention (CDC) issued a Level 2 travel alert last week in response to the situation.
Chikungunya is a viral illness spread to humans mainly through the bite of infected mosquitoes, particularly Aedes aegypti and Aedes albopictus. The warm and humid conditions during the rainy season make it easier for mosquitoes to breed.
Although chikungunya is rare in China, outbreaks are more common in South and Southeast Asia, as well as parts of Africa.
A key symptom of chikungunya is severe joint pain and stiffness, often affecting the hands, wrists, ankles, and knees. This joint pain is usually much worse than what is seen with other viral infections and helps doctors distinguish chikungunya from similar illnesses.
In addition to joint pain, patients may also experience muscle aches, fatigue, and general weakness. A red, patchy rash can appear on the torso, limbs, or face. Symptoms typically begin three to seven days after being bitten by an infected mosquito.
There is no cure for chikungunya, so treatment focuses on relieving symptoms. Doctors usually recommend plenty of rest, staying hydrated, and using medications like painkillers and fever reducers. Nonsteroidal anti-inflammatory drugs (NSAIDs) may also be given to reduce pain and fever during the acute phase of the illness.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
3 hours ago
- Economic Times
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Synopsis Novo Nordisk warned of ongoing competition from copycat versions of its obesity drug Wegovy and signaled possible layoffs due to slowing sales growth, especially in the U.S. The Danish drugmaker, which lost $95 billion in market value after cutting full-year forecasts, said over one million Americans still use compounded GLP-1 drugs despite a U.S. ban. Reuters Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly, the Danish drugmaker warned on Wednesday. Novo, which became Europe's most valuable company worth $650 billion last year on booming sales of Wegovy, is facing a pivotal moment as the medicine loses market share and sees sales growth slow, especially in the United States. It has warned of far slower growth this year - in part due to compounders who have been allowed to make copycat medicines based on the same ingredients as Wegovy due to shortages. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since. The shares were down 3.4% at 1350 GMT. The slide is a huge and abrupt turnaround for the firm that has been one of the world's hottest investment stories, which led to a rapid expansion of manufacturing and sales capacity. Now the firm is eyeing potential cost-cutting measures. "We probably won't be able to avoid layoffs," outgoing CEO Lars Fruergaard Jorgensen told Danish broadcaster DR. "When you have to adjust a company, there are some areas where you have to have fewer people, some (areas) where you have to be smaller." He added, though, that any decision on layoffs would be in the hands of the incoming CEO, company veteran Maziar Mike Doustdar, who takes over on Thursday. On a media call, Jorgensen said the market for copycat versions of Wegovy's class of drugs - known as GLP-1 receptor agonists - was of "equal size to our business" and compounded versions of Wegovy were sold at a "much lower price point". In May, the company said it expected many of the roughly one million U.S. patients using compounded GLP-1 drugs to switch to branded treatments after a U.S. Food and Drug Administration ban on compounded copies of Wegovy took effect on May 22, and it expected compounding to wind down in the third quarter. However, finance chief Karsten Munk Knudsen said on Wednesday that more than one million U.S. patients were still using compounded GLP-1s and that Novo's lowered outlook has "not assumed a reduction in compounding" this year. "The obesity market is volatile," Knudsen told analysts when asked under what circumstances the company could see negative growth in the last six months of the year. The low end of Novo's new full-year guidance range would be for "unforeseen events", such as stronger pricing pressure in the U.S. than forecast, he said. The lower end of the range would imply sales around 150 billion Danish crowns ($23 billion) in the second half of 2025, compared with 157 billion in the same period last year. ENCOURAGING PRESCRIPTION DATA Knudsen reiterated that the company was pursuing multiple strategies, including lawsuits against compounding pharmacies, to halt unlawful mass compounding. Jorgensen said the company was encouraged by the latest U.S. prescription data for Wegovy. While the drug was overtaken earlier this year by rival Lilly's Zepbound in terms of U.S. prescriptions, that lead has narrowed in the past month. Second-quarter sales of Wegovy rose by 36% in the U.S. and more than quadrupled in markets outside the U.S. compared to a year ago, Novo said. While Wegovy's U.S. pricing held steady in the quarter, the company expected deeper erosion in the key U.S. market in the second half, due to a greater portion of sales expected from the direct-to-consumer or cash-pay channel, as well as higher rebates and discounts to insurers, Knudsen said. He said Novo was expanding its U.S. direct-to-consumer platform, NovoCare, launched in March, and may need to pursue similar "cash sales" directly to patients, outside of insurance channels, in some markets outside the United States. COST CUTS The company reiterated its full-year earnings expectations on Wednesday after last week's profit warning. Jorgensen said Novo was acting to "ensure efficiencies in our cost base" as the company announced it would terminate eight R&D projects. "There seems to be a larger R&D clean-out than usual, but we do not know if this reflects a strategic re-assessment or just a coincidence," Jefferies analysts said in a note. Investors have questioned whether Novo can stay competitive in the booming weight-loss drug market. Several equity analysts have cut their price targets and recommendation on the stock since last week. Shares in Novo plunged 30% last week - their worst weekly performance in over two decades. Sales rose 18% in the second quarter to 76.86 billion Danish crowns, below analysts' initial expectations.
Time of India
4 hours ago
- Time of India
28 ventilators lie idle in Hazaribag hosp since 2020, superintendent assures action
1 2 Hazaribag: Since the height of the Covid-19 in 2020, 28 life-saving ventilators have been gathering dust in the ICU of Sheikh Bhikhari Medical College Hospital, unused and forgotten, Hazaribag's Sadar MLA, Pradip Prasad, has raised alarm over this critical healthcare oversight at the health unit. These machines, purchased to combat the pandemic, have yet to see the light of day, leaving patients in dire need to be referred to Ranchi for critical care. Prasad has called this not just negligence but a dangerous gamble with the lives of those seeking medical help. He has demanded swift action from the state health department to rectify this oversight immediately. Speaking to TOI, Prasad said, "These ventilators have been sitting idle for years. No steps were taken to operationalise them, nor was there any effort to appoint trained operators. This is a grave disservice to our community." Prasad also highlighted shone a light on other pressing issues plaguing the hospital, including cleanliness, a shortage of medicines, poorly maintained equipment, and a lack of staff. He stressed the urgent need for solutions. In response to Prasad's concerns, his team met with the hospital superintendent, Dr Anukaran Purti, to delve into these issues. They discussed the hospital's current system, resource status, and the challenges faced on the ground. Purti, acknowledging the gravity of the situation, promised swift action. "I will address these issues, including the ventilators, to ensure they are operational soon," he said.
&w=3840&q=100)
Business Standard
5 hours ago
- Business Standard
WHO updates recommendations on use of antibiotics for Covid-19 patients
The WHO has recommended against the use of antibiotics even in patients with severe Covid when a concurrent bacterial infection is not suspected. The global health body has released updated recommendations for the clinical management of people with Covid which, it said, are based on evidence generated from recent meta-analysis of outcomes of patients treated with antibiotics for Covid. "For patients with non-severe COVID-19 and a low clinical suspicion of a concurrent bacterial infection, we recommend no empirical antibiotics. For patients with severe COVID-19 and a low clinical suspicion of a concurrent bacterial infection, we suggest no empirical antibiotics," the WHO said. The WHO said that as COVID-19 epidemiology and severity have changed, and as emergency measures have subsided, the evidence behind a number of recommendations has changed. In parallel, evolution of health systems and the global environment have meant that the recommendations are implemented in a very different context in 2024 compared to 2020. These guidelines have evolved from the first version in 2020 in line with new information and changing circumstances of the pandemic, the WHO said. "Notable changes to COVID-19 disease over this time have been overall reduced infection rates and reduced disease severity. Emergency measures which were imposed have also been removed, and care for patients with COVID-19 has become more integrated with usual healthcare systems. "This different environment has prompted a review of the scope and content of all existing guidance. In order to maintain a clear focus and relevance, we have removed recommendations which would be considered general medical principles, and those which are no longer specific to the management of COVID-19," the WHO said. The new recommendations on use of antibiotics were prompted by the publication of data from a systematic review and meta-analysis, and the pressing need to address antimicrobial resistance. The WHO said that the updated guidelines are for people directly or indirectly involved in the health care of patients with COVID-19 and post COVID-19 condition. This includes clinicians, allied health care workers, facility managers and hospital administrators. The SARS-CoV-2 continues to infect several thousands of people daily leading to preventable morbidity and mortality across the world, the WHO said. The roll-out of vaccines and treatment for COVID-19, and increasing population immunity from infection has substantially reduced hospitalization, severity of disease, and mortality. "However, the virus continues to evolve in terms of infectivity, immune escape, and disease severity. This guideline robustly and transparently addresses the changing landscape and evidence availability, and the continual development of treatment and management strategies for COVID-19," the WHO stated. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
